Elaine Hochberg

Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY.

Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA.

Forest Pharmaceuticals, Inc. manufactures, distributes, and sells forest-branded prescription products in the United States and Puerto Rico. The company is headquartered in St. Louis, MO.

The Metropolitan Opera Guild, Inc. was founded in 1935. The non-profit company is based in New York, NY. The company's mission is to enrich people's lives through a deeper appreciation of opera while supporting the Metropolitan Opera by helping to expand its reach to a wider audience. The company offers tours of the Metropolitan Opera House, Guild School programs that enhance student learning, and the annual Opera News Awards celebration. Additionally, the company offers a subscription to Opera News with a discount of 68% off the cover price and digital access.

Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.

Elaran LLC is a business strategy and management firm. The private company is based in New York.